IM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma business lazer focused on the research and development of therapeutics to treat immune disorders, viral diseases and a number of kinds of cancers, today said that its Chief Executive Officer, Thomas K. Equels, will appear live now as a guest on FOX Business Network’s The Claman Coutdown and Cheddar’s Opening Bell.

Mr. Equels intends to explore the therapeutic potential of Ampligen as both an early-onset remedy for and prophylaxis from the Wuhan coronavirus which has so far infected roughly 40,000 people and is currently responsible for more deaths than the initial highly pathogenic human coronavirus (SARS). Because of Ampligen’s unique immune stimulation capacities based on peer reviewed and published animal and human research on influenza, a vaccine generated by combining Ampligen and inactivated Wuhan coronavirus could potentially protect against other types of coronavirus and future mutations of the Wuhan coronavirus.

Ampligen has generated a generally well-tolerated safety profile based on roughly 100,000 IV doses in human clinical trials to date, in addition to Phase 1 safety studies in intraperitoneal (IP) and intranasal (IN) administration.

Coronaviruses are a large family of viruses, including the deadly Severe Acute Respiratory Syndrome (SARS). Following a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States’ National Institutes of Health contracted studies to evaluate potential treatments for SARS. Ampligen attained a 100% survival rate – as compared to 100% mortality – in clinically achievable human dose amounts in SARS animal experiments.

Mr. Equels will also appear on The Claman Countdown on the FOX Business Network with host Liz Claman between 3 PM and 4 PM ET.

finviz dynamic chart for  aim

To get these stocks much faster (real-time) with alerts, check out the tool we use here. There’s nothing like it on the market.

AIM ImmunoTech News From Google